National Changes in Diabetes Care Practices during the COVID-19 Pandemic: Prospective Study of US Adults

Background There is a lack of nationally representative prospective data on the impact of the COVID-19 pandemic on diabetes care and management in adults with type 2 diabetes. We examined changes in diabetes care and management practices before and after the onset of the COVID-19 pandemic. Methods Using the National Health Interview Survey, we analyzed data from 870 adults living with type 2 diabetes who were interviewed in 2019 and re-interviewed between August and December 2020. Exposure to the COVID-19 pandemic was defined by year of survey (2019, pre-pandemic; 2020, pandemic). We estimated percent change in past year blood sugar check by a health professional and current use of blood sugar lowering medication overall and by sociodemographic subgroups. Results Receiving an annual blood sugar test fell by −3.3 percentage points (pp) (95% CI −5.7, −1.0), from 98.3% in 2019 to 95.0% in late 2020. The reduction in annual blood glucose testing was largely consistent across socio-demographic groups and was particularly pronounced among adults not working and adults aged 65 years and older. In the same time period, current use of diabetes medications increased by +3.8 pp (0.7, 6.9), from 85.9% to 89.7%. The increase in medication use was most pronounced among individuals aged 40–64-year old, employed, and those living in large central metropolitan areas. Conclusions Nationally, adults with Type 2 diabetes reported a reduction in annual blood glucose testing by a health professional and an increase in diabetes medication usage during the COVID-19 pandemic. If sustained after the end of the COVID-19 public health emergency, these changes have implications for national diabetes management and care.


47
Diabetes is a complex chronic condition requiring routine monitoring and regular 48 medication. At minimum, the American Diabetes Association (ADA) recommends having an 49 annual blood sugar check 1 and when needed, pharmacologic treatments such as metformin or 50 other agents, including combination therapy 2 in adults with diabetes. There has been much 51 concern that the COVID-19 pandemic has impacted diabetes care. Disruptions to health services 52 3,4 , changes to routine care 4 , and fear of getting severely ill from the virus 5 may have prevented 53 some individuals living with diabetes from getting the care they need. Lack of access to health 54 services has been associated with diabetes-related complications such as cardiovascular disease, 55 kidney disease, neuropathy, or blindness 5 . Conversely, access to healthcare has been associated 56 with controlled levels of blood glucose, blood pressure, and blood lipids 6 , which collectively 57 prevent the onset of diabetes-related complications 7,8 . 58 Several studies indicate that that people with diabetes experienced challenges with 59 managing their disease during the pandemic. For example, an online community-based survey 60 indicated that 25% of people needing an insulin pump or continuous glucose monitoring supplies 61 had delays or difficulties in obtaining them and that 1 in 6 persons with diabetes had difficulty 62 needing insulin, as of April 2020 9 . However, these data do not provide a clear picture regarding 63 how individuals' diabetes care and management have changed in response to the pandemic.

64
Identifying the indirect impact of the pandemic is critical to understanding the needs and 65 requirements of those living with diabetes for future public health emergencies and the state of 66 diabetes care as we move into post-public health emergency recovery. Using prospective data 67 from a nationally representative sample of adults interviewed in 2019 and re-interviewed in 68 2020, we examined changes in annual blood sugar checks and use of current medication to lower . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2023. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2023. ; https://doi.org/10.1101/2023.08.06.23293722 doi: medRxiv preprint 114 We estimated the prevalence of annual blood sugar checked and taking medication to 115 lower blood sugar for diabetes control in 2019. Next, we estimated the average within-person 116 change in each outcome from 2019 to 2020. Changes were estimated for the total sample as well 117 as by age, sex, race, smoking status, marital status, urbanicity, insurance type, education level, 118 and employment status. We computed the unadjusted change in each stratum, as well as the 119 marginally adjusted change accounting for other sociodemographic groups in the analysis.

120
All data were analyzed using SAS version 9.4 and SUDAAN version 11.0.1, accounting 121 for the complex survey design.

123
The distribution of the sociodemographic characteristics of adults with type 2 diabetes at 124 baseline (2019) are shown in Table 1.
125 Table 2  136 DISCUSSION . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2023. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

159
Respondents reported an average increase in use of medications to lower blood sugar in 160 August-December 2020 compared to 2019. This finding is consistent with reports from a 161 previous study using an online survey, which showed that among respondents with type 2 162 diabetes who reported a change in the intake of diabetes medication, a greater proportion of 163 individuals took medications more regularly during the pandemic compared to before the 164 pandemic 13 . The increase in diabetes usage during the early pandemic could be explained by one 165 of two scenarios: 1. Patients were previously prescribed a diabetes lowering medication but had 166 not started it or not taking it for some reason; or 2. Patients previously not eligible for diabetes 167 medication based on their blood sugar values, were now eligible for blood sugar lowering 168 medication. Alternatively, persons may have been more diligently checking their blood sugar at 169 home, identified rising blood sugars, contacted their provider, and received newly prescribed 170 blood sugar lowering medication. It is noteworthy that individuals with diabetes were able to get 171 refills on prescriptions without visiting the doctor in 2020, whereas they had to return to their 172 doctor to get refills by 2021.

173
In our analysis, we found that those living in large central metropolitan areas and in the 174 40-64 years old age group reported a higher increase in the intake of medication to lower blood 175 sugar in 2020 compared to those living in less urban areas or younger/older age groups.
176 Individuals living in urban areas may have better infrastructure to obtain medications 14 , better 177 access to telehealth services 15 , and be able to better afford medications compared to rural places 178 14 . Individuals aged 40-64 reported an increase in medication to lower blood sugar. These 179 individuals may also be more likely to have access to internet and telehealth services 16 to enable 180 discussion with providers on the need for medication despite not being able to visit the provider.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2023. ; https://doi.org/10.1101/2023.08.06.23293722 doi: medRxiv preprint Broadly, our findings regarding both medication and testing are consistent with other 182 national studies examining diabetes testing and medication usage during the pandemic. A 183 previous study using electronic medical records in the United States during the same time period 184 found a decrease outpatient visits and HbA1c testing during the pandemic, without evidence of 185 reduced medication fills or glucose control 17 . Considering serial cross-sectional data from NHIS 186 respondents, the prevalence of blood glucose checking in US adults with diabetes was 96.8% in 187 2019 compared with 94.2% in 2021, suggesting that the drop in glucose checking by health 188 professionals was sustained even in the second year of the pandemic 18 . Similarly, reductions in 189 diabetes testing have also been reported in England 19 . Reductions in HbA 1C testing is of concern 190 due the importance of glucose monitoring for clinical treatment decisions and feedback to 191 patients on diabetes management 19 . 192 Our study has several strengths. First, we used nationally representative prospective data 198 for responses to having blood sugar checked by a health professional in the past 12 months. We 199 were not able to assess whether changes in diabetes testing and medication resulted from changes 200 in diabetes control due to lack of laboratory data.

202
Using data from prospectively followed adults drawn from a nationally representative 203 sample, we found a reduction in annual blood sugar checks by healthcare providers and an . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2023. 204 increase in reporting of taking medication to lower blood sugar in 2020 compared to 2019, 205 among adults with type 2 diabetes. Despite a reduction in testing, there was an increase in those 206 taking medication for diabetes. The increase in medication warrants further examination. 232 KV is the guarantor of this work and, as such, had full access to all the data in the study and takes 233 responsibility for the integrity of the data and the accuracy of the data analysis.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.